| Ibrutinib and venetoclax for first-line treatment of CLL N Jain, M Keating, P Thompson, A Ferrajoli, J Burger, G Borthakur, ... New England Journal of Medicine 380 (22), 2095-2103, 2019 | 487 | 2019 |
| 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial CD DiNardo, A Maiti, CR Rausch, N Pemmaraju, K Naqvi, NG Daver, ... The Lancet Haematology 7 (10), e724-e736, 2020 | 242 | 2020 |
| Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase … H Kantarjian, F Ravandi, NJ Short, X Huang, N Jain, K Sasaki, N Daver, ... The Lancet Oncology 19 (2), 240-248, 2018 | 215 | 2018 |
| Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia CD DiNardo, CA Lachowiez, K Takahashi, S Loghavi, L Xiao, T Kadia, ... Journal of Clinical Oncology 39 (25), 2768-2778, 2021 | 207 | 2021 |
| Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens CA Lachowiez, S Loghavi, TM Kadia, N Daver, G Borthakur, ... Blood advances 4 (7), 1311-1320, 2020 | 130 | 2020 |
| Long‐term follow‐up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic‐phase chronic myeloid leukemia K Naqvi, E Jabbour, J Skinner, K Anderson, S Dellasala, M Yilmaz, ... Cancer 126 (1), 67-75, 2020 | 113 | 2020 |
| Acute promyelocytic leukemia current treatment algorithms M Yilmaz, H Kantarjian, F Ravandi Blood cancer journal 11 (6), 123, 2021 | 106 | 2021 |
| Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic … TM Kadia, PK Reville, G Borthakur, M Yilmaz, S Kornblau, Y Alvarado, ... The Lancet Haematology 8 (8), e552-e561, 2021 | 102 | 2021 |
| Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens A Maiti, CR Rausch, JE Cortes, N Pemmaraju, NG Daver, F Ravandi, ... Haematologica 106 (3), 894, 2021 | 101 | 2021 |
| Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia A Maiti, CD DiNardo, NG Daver, CR Rausch, F Ravandi, TM Kadia, ... Blood cancer journal 11 (2), 25, 2021 | 99 | 2021 |
| Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax K Kim, A Maiti, S Loghavi, R Pourebrahim, TM Kadia, CR Rausch, ... Cancer 127 (20), 3772-3781, 2021 | 98 | 2021 |
| Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline … EJ Jabbour, K Sasaki, F Ravandi, NJ Short, G Garcia‐Manero, N Daver, ... Cancer 125 (15), 2579-2586, 2019 | 94 | 2019 |
| Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials TA Yap, N Daver, M Mahendra, J Zhang, C Kamiya-Matsuoka, ... Nature medicine 29 (1), 115-126, 2023 | 88 | 2023 |
| Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia? M Yilmaz, F Wang, S Loghavi, C Bueso-Ramos, C Gumbs, L Little, X Song, ... Blood cancer journal 9 (2), 7, 2019 | 84 | 2019 |
| Clinical experience with venetoclax combined with chemotherapy for relapsed or refractory T-cell acute lymphoblastic leukemia G Richard-Carpentier, E Jabbour, NJ Short, CR Rausch, JM Savoy, ... Clinical Lymphoma Myeloma and Leukemia 20 (4), 212-218, 2020 | 83 | 2020 |
| Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B‐cell acute lymphoblastic leukemia E Jabbour, NJ Short, JL Jorgensen, M Yilmaz, F Ravandi, SA Wang, ... Cancer 123 (2), 294-302, 2017 | 83 | 2017 |
| Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors M Yilmaz, A Lahoti, S O'Brien, GM Nogueras‐González, J Burger, ... Cancer 121 (21), 3894-3904, 2015 | 72 | 2015 |
| Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: no change in the level of CD19 expression E Jabbour, J Düll, M Yilmaz, JD Khoury, F Ravandi, N Jain, H Einsele, ... American journal of hematology 93 (3), 371-374, 2018 | 69 | 2018 |
| Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic‐phase chronic myeloid leukemia K Naqvi, E Jabbour, J Skinner, M Yilmaz, A Ferrajoli, P Bose, P Thompson, ... Cancer 124 (13), 2740-2747, 2018 | 68 | 2018 |
| Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial N Jain, M Keating, P Thompson, A Ferrajoli, JA Burger, G Borthakur, ... JAMA oncology 7 (8), 1213-1219, 2021 | 67 | 2021 |
